title: [An extended operation for scirrhous gastric cancer--its significance and procedure].
abstract: We have been performing an extended operation for scirrhous gastric cancer, namely left upper abdominal exenteration plus Appleby's method, and compared the prognosis among macroscopic subtype classifications. The surgical procedure of left upper abdominal exenteration plus Appleby's method is to resect the neighboring organs of the stomach in an en bloc fashion. It consists of total gastrectomy, partial pancreatectomy, splenectomy, transverse colectomy, cholecystectomy, resection of the left adrenal gland, and ligation and resection of the common hepatic artery. D4 lymph node dissection is carried out. Extended operations were performed for 45 cases of P0-1 scirrhous gastric cancer in 1983-1990. There were 25, 17 and 3 cases of giant fold type, erosive type and stenotic type scirrhous gastric cancers, respectively. Positive lymph node metastases were found in 64% of giant fold type cases and 82% of erosive type cases. In Po, T3-4 cases, cytology of intraoperative peritoneal lavage was positive in 27% of giant fold type cases and 50% of erosive type cases. Although there were no obvious macroscopic invasions found during the operative procedure, later histological study showed invasion to the left adrenal gland in 14% of giant fold type cases and 0% of erosive type cases, and invasion to the transverse colon in 21% of giant fold type cases and 15% of fold type and erosive type scirrhous gastric cancer according to the histological invasion of transverse colon were 25% in positive cases and 27% in negative cases (p = 0.27), 0% in positive cases and 27% in negative cases (p = 0.27), respectively. In giant fold type scirrhous gastric cancer, the extended operation is favorable. In erosive type scirrhous gastric cancer, peritoneal dissemination is observed with a high incidence. Therefore, prophylactic therapy is significant.
authors.affiliation: Department of Surgery, Center for Adult Diseases, Osaka, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Hiratsuka
authors.forename: H
authors.initials: H
authors.lastname: Furukawa
authors.forename: T
authors.initials: T
authors.lastname: Iwanaga
authors.forename: S
authors.initials: S
authors.lastname: Tamura
authors.forename: T
authors.initials: T
authors.lastname: Yasuda
authors.forename: H
authors.initials: H
authors.lastname: Nakano
authors.forename: S
authors.initials: S
authors.lastname: Nakamori
authors.forename: H
authors.initials: H
authors.lastname: Ohigashi
authors.forename: M
authors.initials: M
authors.lastname: Kameyama
authors.forename: Y
authors.initials: Y
authors.lastname: Sasaki
mesh_terms: D002293:Adenocarcinoma, Scirrhous / Q000473:pathology / Q000601:surgery*; D002763:Cholecystectomy; D003082:Colectomy; D005743:Gastrectomy / Q000379:methods* / Q000401:mortality; D006801:Humans; D007263:Infusions, Parenteral; D008207:Lymphatic Metastasis; D016685:Mitomycin / Q000008:administration & dosage; D009361:Neoplasm Invasiveness; D010180:Pancreatectomy; D013156:Splenectomy; D013274:Stomach Neoplasms / Q000473:pathology / Q000601:surgery*
chemical_list: D016685:Mitomycin